TOCCA Life Holdings, Inc. (TLIF) 股价表现
查看TOCCA Life Holdings, Inc.股价及公司表现,包括市值,涨跌幅,市盈率,以及历史及当前股价。
昨收 0.00
52周最高 0.01
今开 0.00
52周最低 0.00
振幅 0.00%
市盈率 0%
成交额
0.00
亿
市净率 0%
换手率 0.00%
总市值
0.00亿
股息 0
总股本
1.18
亿
股息收益率 0%
每手股数 1
TOCCA Life Holdings, Inc.公司介绍
The Company has had several business models throughout its organizational history. In January 2015, change in control of the Company occurred and as a result a new business model was adopted. The Company, through it's subsidiary Xirxi Co., Ltd, a British Virgin Islands corporation with offices in Bangkok and Thaliand ("Xirxi"), is a business-to-consumer and business-to-business ecommerce company in Asia. It is expected that operations through this subsidiary will be winding down in order for the Company to concentrate all of its efforts into the business model of it's other subsidiary TOCCA Life Coaching, Inc.
In focusing on its new business model, TOCCA Life Holdings, Inc., through its subsidiary TOCCA Life Coaching, Inc., a Florida corporation, offers structured sober living residences and prescribed clinical laboratory toxicology testing while providing the general public informative detection practices and products for the early detection of the disease of addiction.
TOCCA Life Coaching, Inc. is in the process of organizing and systematizing sober living residences in the South Florida area initially and then expanding nationally through internal growth and acquisitions which will capture the inherent 500% gross land lord tenant margins while complementing the network with a state of the art laboratory that provides illicit and prescribed drug monitoring. The clinical toxicology services to monitor drug use can exponentially escalate gross profit margins with anticipated average revenues of $700 per test per client up to 3 times per week on a reoccurring basis as prescribed by doctors to ensure the clients' accountability while living in the residence, providing a safe residence for clients and safe work environment for staff. The anticipated revenues are inclusive and post revenue share agreement costs which finance the laboratories in part.